To: 5.1.2e , 5.1.2e [5.1.2e @tandf.co.uk]
Cc: 5.1.2e 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e 5.1.2e [5.1.2e @p-95.com]
From: 5.1.2e
Sent: Thur 2/11/2021 9:34:22 AM
Subject: [Spam] RE: Epidemiologic Methods for Evaluating Vaccination Programmes
Received: Thur 2/11/2021 9:36:32 AM
Figures and Tables (Paddy) log.xlsx
Permissions details (Paddy).docx
Chapter 14 Tables.docx
Petts 2004 MMR risk discussion.pdf

Dear 5.1.2e

Having checked with 5.1.2e, I thought it might be easier if I responded directly to you regarding permissions etc for "my" bits. I hope that's OK.

So I've gone through the chapters I was mainly involved with, and expanded the log (Excel file *Figures and Tables (Paddy) log*, attached) with two columns: Flagged by 5.1.2e (Y/N) and Further details. In connection with these responses I had the following further points:

1. Figure 9.5: I got permission via RightsLink, see item CPF09 in attached WORD file *Permissions details (Paddy)*.
2. Chapter 14 Summary Table: indicated as missing, but it's in the attached document *Chapter 14 Tables*.
3. Table 6.2: I need your advice with this one. This table is reproduced from Table 1 in the attached paper *Petts (2004)* from the journal *Health, Risk and Society* (published by 5.1.2e. The original source is quoted as a leaflet from Health Promotion England. I imagine this must be Crown Copyright (and hence OK to reproduce without permission) but I can't find any trace of the original leaflet on the web. I wondered if you (5.1.2e had details, as publishers of the article.

The other queried figures and tables in this list were produced from scratch by us. Where real data were used, this was always taken from a publication referred to in the box where the figure or table appears. I've indicated this explicitly for the figures.

I hope this answers your queries for these chapters

Best wishes

5.1.2e

From: 5.1.2e , 5.1.2e < 5.1.2e @tandf.co.uk>
Sent: 10 February 2021 10:09
To: 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @open.ac.uk>; 5.1.2e 5.1.2e < 5.1.2e @p-95.com>
Subject: RE: Epidemiologic Methods for Evaluating Vaccination Programmes

5.1.5

Hi 5.1.2e

Thank you, that must have not downloaded for me when I transferred the dropbox files! Sorry about that. I'm afraid it only eliminates a few however, and there are still the below which need attention. I assume most of the tables have been created by yourselves, at which point they obviously don't incur permissions issues so please just enter 'author's own' and we can discount those ones. If there's anything else I can do please do let me know.

Figure 1.1	Vaccine vials with vaccine vial monitors	
Table 2.1	Main differences between T-independent and T-dependent B cell responses	
Figure 4.2	Schematic representaiton of the incidence of a highly infectious immunising infection and the proportion of the population that is susceptible to it over time	

Figure 4.3	Transmission chains for measles in healthcare workers	
Figure 4.4 x2	Schematic representation of an infection with R_0 = 3 soon after the introduction of one infectious individual (the index case).	
Figure 4.5	Schematic representation of ages at infection (dots) and death (crosses) for ten individuals	
Figure 4.6	A heterogeneous population with two subgroups.	
Figure 4.7	Age of participants and their contacts for Belgium (left) and Germany (right). Darker shades correspond to lower contact rates.	Reproduced from (Mossong, et al., 2008)
Figure 4.8	The SIR compartmental model.	
Table 4.1	Low and high range estimates of Ro for selected infectinos	
Table 4.2	Number of cases by 5-year age group 0-4, 5-9,..., 55-59 years, with age group midpoints (years).	
Table 4.3	Baseline US values and percentage reduction (compared to baseline 5% vaccine coverage in children) in hospitalisations and deaths due to influenza at different childhood coverage levels.	
Figure 5.7	Shift in the age distribution of rubella cases presenting at outpatient departments of hospitals within the Athens region	
Table 5.1	Low and high estimates of R_0 from (Anderson & May, 1992), the critical immunisation threshold, VE estimates and the critical vaccination threshold, for selected infections.	
Table 6.1	Concerns most frequently identified in 145 studies	
Table 6.2	Comparison of the serious effects of the disease and reactions to MMR	Source: MMR: The Facts (2002) Health Promotion England, reproduced in (Petts & Niemeyer, 2004).
Figure 7.1	Nomenclature of territorial units for statistics (NUTS) – 3 regions of Greece, 2016	
Figure 7.2	Difference between vaccination coverage (VC) estimates based on health insurance claims (ASHIP) and kindergarten entry examination (KEE) data, by vaccine and dose, Schleswig-Holstein, Germany	
Figure 7.4	Proportion of vaccine-related reports categorised as positive or neutral, by country.	(Larson et al., 2013).
Figure 8.5	The surveillance pyramid with examples of sources of data. † Fatal cases in surveillance.	
Figure 8.6	Laboratory reports of Haemophilus influenzae infection b by quarter and year, England, 1990-2006. The arrows indicate the introduction of universal Hib vaccination in 1992 and the Hib booster campaign in 1993	(Anonymous, 2015).
Figure 8.9	Map of India with the states of Uttar Pradesh and Bihar in blue.	
Table 8.1	Validity of case definition	
Figure 9.1	Hepatitis seroprevalence by age in Antananarivo, 2004.	
Figure 9.2	Proportion of women seronegative for rubella by age group, Cambodia, 2012.	
Figure 9.3	Percentages with protective levels of serum bactericidal antibodies, by age group, in three serological surveys.	

Table 9.1	Percentage seropositive in children aged 6 – 9 months by poliovirus type and year, Kano, Nigeria.	
Figure 10.1	Individual effects and population impact of vaccination. See text for details.	
Figure 10.4	Incidence of anogenital warts (Left) and chlamydia (Right) in women, by age group, 2004-12. Full lines: 15-19 years; dashed lines: 20-24 years; dotted lines: 25-29 years.	
Figure 10.6	RDD design	
Figure 10.7	proportions fully vaccinated by quarter and year of birth and the risks of cervical dysplasia	
Figure 10.8	Distribution of outbreak sizes of 41 outbreaks with at least 2 cases.	
Figure 11.1	Causes of outbreaks of vaccine preventable diseases in the context of a vaccination programme.	
Figure 11.2	Schematic representation of causes of measles outbreaks.	
Figure 11.3	Number of reported diphtheria cases by year, (former) Soviet Union, 1965-1995.	
Figure 11.4	A. Proportion of the 2001 birth cohort who received MMR-1, by municipality, The Netherlands, January 2004. B. Number of notified rubella cases per 100.000 population, by municipality, The Netherlands, 1st September 2004-31st July 2005.	
Figure 11.5	Mumps cases by age and measles-mumps-rubella (MMR) vaccination status, Norway, September 2015–May 2016 (n=231*).	
Figure 11.6	Number of cases of a hypothetical vaccine preventable disease over time, with regular epidemic cycles pre-introduction of a vaccination programme, a 'honeymoon period' and three 'post-honeymoon' epidemics	
Figure 11.7	Epidemic curve and key time delays in vaccination in Juba, South Sudan, 2015.Bars represent numbers of suspected cases, defined as all individuals with acute watery diarrhoea regardless of dehydration.	
Figure 11.8	Cases of invasive meningococcal W disease by week of onset and pilgrim status, England and Wales, 2000 and 2001 (up to week 19).	
Figure 11.9 x2	Health promotion poster aimed at female (left) and male (right) post-secondary students, urging them to comply with mumps vaccination recommendations	
Table 11.1	Reasons for not being vaccinated, measles patients (n=272), Duisburg, Germany 2006	
Figure 12.1	The stepped wedge design with 3 areas.	
Figure 13.1	Vaccine effectiveness of acellular pertussis vaccine by confirmation method and duration of paroxysmal cough	
Table 13.1	Effectiveness of 2 doses of rotavirus vaccine against confirmed wild-type infection	
Table 13.2	Numbers infected per week in vaccinated and unvaccinated groups	
Table 14.1	Numbers of vaccinated and unvaccinated students and cases	
Table 14.2	Cases and person-time by vaccination status and prior history of zoster	
Table 14.3	Numbers of pertussis cases and contacts by vaccination status	

Table 14.5	SUMMARY TABLE- MISSING	
Table 15.1	Summary Table	
Figure 16.2	Rate-based and risk-based vaccine effectiveness for constant rate-based VE equal to 50%.	
Figure 16.3	Rate-based and risk-based vaccine effectiveness for constant risk-based VE equal to 50%.	
Figure 16.4	Individual protection in vaccinated individuals	
Figure 16.5	Age-specific effectiveness of whole-cell pertussis vaccine.	
Table 16.1	Mumps vaccine effectiveness (%, with 95% confidence intervals) by age group and number of vaccine doses	
Table 16.2	Average incidence rates of varicella (per thousand person years) in vaccinated and unvaccinated children, and rate-based vaccine effectiveness, by study period	
Table 16.3	Risks of varicella in vaccinated and unvaccinated children, and risk-based vaccine effectiveness, by study period	
Table 16.4	Effectiveness of pertussis vaccine by age (years), with 95% confidence intervals (CI).	
Table 17.1	Frequencies of severe adverse events for selected vaccines (abbreviations below)	
Figure 18.1	Weekly cases of narcolepsy, Finland, 2009-2010.	
Figure 19.1	Risk periods for febrile convulsions after each dose of DTP vaccine. The numbers represent days since the last DTP dose (day 0).	
Figure 19.2	Risk periods for febrile convulsions after MMR vaccine. The numbers represent days since MMR vaccination (day 0).	
Figure 19.3	Risk periods for autism after MMR vaccine. The numbers represent months since MMR vaccination (day 0).	
Figure 19.4	Numbers of intussusceptions by 10-day interval before and after each vaccine dose	
Table 19.1	Relative risk (95% CI) of regressive autism after MMR vaccination	
Table 19.2	Relative risk of SIDS in defined post-DTP risk periods	
Table 19.3	Relative risk (95% confidence interval) of asthma exacerbation in the 2 weeks following influenza vaccination, by analysis method, in the 1993-4, 1994-5 and 1995-6 influenza seasons	
Table 19.4	Relative risk of consultation for asthma and COPD, with 95% confidence interval	
Figure 20.1	ITP cases by interval (in 6-week periods) between MMR and ITP	
Figure 20.2	Case interval and control intervals for MS relapse study	
Table 20.1	Numbers of convulsions and total follow-up time in exposed and unexposed groups	
Table 20.2	Cases of autism and autism spectrum disorders, and person time in exposed and unexposed groups	

Table 20.3	Cases and controls with odds ratio (OR) and 95% confidence interval (CI)	
Table 20.4	Odds ratio of MS according to exposure definition and control type	
Table 20.5	Total number and relative incidence (RI) of selected adverse events after varicella vaccine	
Table 20.6	Bell's palsy episodes, relative incidence (RI) and 95% CI by risk period	
Table 20.7	Number of events relative incidence (RI) and 95% CI by dose	
Table 20.8	Summary Table	
Figure 21.1	Example of a value tree related to HPV vaccination in boys, showing the benefits for boys only.	
Table 21.1	The eight steps of the ProACT-URL framework	
Table 21.2	A benefit-risk assessment of HPV vaccination in boys.	
Table 21.3	Benefit-risk assessment of HPV vaccination in boys and young men (16-26 years).	
Table 21.4	Vaccine-specific benefits and risks of sustaining routine childhood immunisation in Africa during the COVID-19 pandemic	
Table 21.5	Effect of rotavirus vaccination programme as compared with no rotavirus vaccination programme, on deaths and hospitalizations associated with diarrhoea and intussusception in Mexico.	
Table 21.6	Benefit-risk of rotavirus vaccination in a birth cohort of 1 million Japanese children followed for 5-years post-vaccination.	
Table 21.7	Rotavirus deaths averted versus excess intussusception deaths caused under age-restricted and age-unrestricted rotavirus vaccination strategies, from Patel 2012	
Table 21.8	Estimated annual benefit-risk ratio and difference of hospitalizations due to rotavirus vaccination in France, assuming various vaccine coverages, with and without accounting for the indirect effects of vaccination	
Table 21.9	Risks and benefits of the HPV vaccine in terms of QALY change	
Table 21.10	Projected number of cases, deaths and QALYs lost due to Guillain-Barré Syndrome and meningococcal disease.	
Table 21.11	Estimated AEFI-associated years lived with disability (YLD) per 1,000,000 persons (with 95% uncertainty intervals), following vaccination with MMR, DTP and MenC (age group 13m-4yrs)	
Table 21.12	DALYs estimation following measles vaccination, and following measles infection in childhood.	

Best wishes,

5.1.2e

5.1.2e

2 Park Square, Milton Park, Abingdon, OX14 4RN UK

5.1.2e @informa.com

From: 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>
Sent: 04 February 2021 20:03
To: 5.1.2e , 5.1.2e < 5.1.2e @tandf.co.uk>; 5.1.2e < 5.1.2e @open.ac.uk>; 5.1.2e 5.1.2e < 5.1.2e @p-95.com>
Subject: RE: Epidemiologic Methods for Evaluating Vaccination Programmes

Dear 5.1.2e

Sorry, when looking a bit more closely, I noticed that many items in your colourful table at the bottom of your e-mail are included in this log:
https://www.dropbox.com/home/Vaccine%20Book%20Handover/Log_figures_tables?preview=Permissions+log+(Paddy).xlsx

Could you please let us know which ones remain?

With best wishes,

5.1.2e

From: 5.1.2e , 5.1.2e < 5.1.2e @tandf.co.uk>
Sent: dinsdag 2 februari 2021 14:45
To: 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @open.ac.uk>; 5.1.2e 5.1.2e < 5.1.2e @p-95.com>
Subject: [Spam] Epidemiologic Methods for Evaluating Vaccination Programmes

Dear 5.1.2e

I'm pleased to let you know that I have finally completed my editorial checks on your manuscript, and everything's looking good. There are just a few things I need to check with you before I can submit your manuscript to production.

Blurb
This is the blurb we have on file for your book:
Vaccination programmes are a vital public health tool and are present in virtually every country in the world. Promoting an understanding of the implementation issues that vaccination programmes face, this textbook outlines and discusses how epidemiologic methods can be used to measure the incidence of vaccine preventable disease.

Written by expert practitioners in an accessible and concise style, this practical book is accompanied by a companion website with exercises, data sets and case studies which allow readers to practice analyses and approaches on real life data and problems.

Suitable for professionals working in public health, biology, and those working in health economics, health management, and vaccine development, Epidemiologic Methods for Evaluating Vaccination Programmes also serves as a textbook for postgraduate students in public health and epidemiology.

1. The middle paragraph of the blurb should include a description of the contents of each section of the book. 5.1.5 5.1.5
2. You'll noticed that I've underlined the 5.1.5. As far as I was aware, we were only planning on an eResource (content listed on your book's product page on Routledge.com). A companion website generally requires a little more planning and is more complex than just submitting content (e.g I'd need to draw up a site map, etc). It's not a disaster if a CW is still the plan, I'll just need to know so that I can get to work on it.
3. Regardless of whether we decide to go with a CW or an eresource, I'll still need the content to be submitted ASAP- 5.1.5 5.1.5

Author bios

5.1.2e 5.1.2e is head of department for early warning and surveillance, at the Centre for Epidemiology and Surveillance of Infectious diseases of the National Institute for Public Health and the Environment (RIVM) in the Netherlands. 5.1.5 5.1.5

5.1.2e is emeritus professor of statistics at the Open University (OU), UK. Prior to joining the OU in 1998, he was for 11 years statistician at the Immunisation Division of the Communicable Disease Surveillance Centre, within the Public Health Laboratory Service for England and Wales 5.1.5 5.1.5

5.1.2e 5.1.2e is head of data science at P95 Belgium, a scientific service-providing company focused on pharmacovigilance and epidemiology related to vaccines and infectious diseases. 5.1.5 5.1.5

5.1.5

Title discrepancy

Our system has: Epidemiologic Methods for Evaluating Vaccination Programmes
MS has: Vaccination Programmes: Epidemiology, Monitoring, Evaluation

5.1.5

ToC/Chapter title discrepancies

Chapter 4- MS has: Dynamics of vaccine-preventable infectious diseases
ToC has: Dynamics of controlling vaccine preventable diseases
Chapter 6- MS has: Vaccination: a societal perspective
ToC has: Vaccine risks: a societal perspective
Chapter 10- MS has: Assessing and monitoring impact
ToC has: Assessing impact

5.1.5

Missing Figures

The following figures (please find attached) have been supplied in the incorrect format. 5.1.5

5.1.5 - do you think this will be possible?

Figure 7.3- Epidemiologic Methods for Evaluating Vaccination Programmes
Figure 7.5- Volume of social media messages related to vaccination, April – September 2020.
Figure 8.1- The number of reported clinical measles cases by cause (bars) and the positive predictive value of the clinical case definition (blue line), in different stages of measles control in the UK
Figure 8.2- The number of rotavirus reports from virological laboratories and the number of GP consultations in <5 year olds for acute gastro-enteritis per 100.000 children, by week, 3-week moving average, The Netherlands, August 1999-August 2014
Figure 8.6- Laboratory reports of Haemophilus influenzae infection b by quarter and year, England, 1990-2006. The arrows indicate the introduction of universal Hib vaccination in 1992 and the Hib booster campaign in 1993
Figure 8.8- Incidence of overall, vaccine-type, and non-vaccine-type invasive pneumococcal disease in the Kilifi Health and Demographic Surveillance System, 1999–2016 (A) In children aged <5 years; (B) In individuals aged ≥15 years.
Figure 11.1- Causes of outbreaks of vaccine preventable diseases in the context of a vaccination programme.
Figure 11.3- Number of reported diphtheria cases by year, (former) Soviet Union, 1965-1995.
Figure 11.5- Number of reported diphtheria cases by year, (former) Soviet Union, 1965-1995.

I'm afraid the below one is totally my fault as I deleted it by mistake while completing my edits! If possible, would you mind resupplying this summary table?
Figure 21.6- Summary Table

Permissions queries
For the below table, please only pay attention to the orange column 5.1.5 column. I have put together the below table to show which figures/tables either have no source supplied, *or* have a source supplied but no confirmation that permission has been sought from that source. 5.1.5

5.1.5

Figure 1.1	Vaccine vials with vaccine vial monitors	
Table 2.1	Main differences between T-independent and T-dependent B cell responses	
Figure 4.2	Schematic representaiton of the incidence of a highly infectious immunising infection and the proportion of the population that is susceptible to it over time	
Figure 4.3	Transmission chains for measles in healthcare workers	
Figure 4.4 x2	Schematic representation of an infection with R_0 = 3 soon after the introduction of one infectious individual (the index case).	
Figure 4.5	Schematic representation of ages at infection (dots) and death (crosses) for ten individuals	
Figure 4.6	A heterogeneous population with two subgroups.	
Figure 4.7	Age of participants and their contacts for Belgium (left) and Germany (right). Darker shades correspond to lower contact rates.	Reproduced from (Mossong, et al., 2008)
Figure 4.8	The SIR compartmental model.	
Table 4.1	Low and high range estimates of Ro for selected infectinos	
Table 4.2	Number of cases by 5-year age group 0-4, 5-9,..., 55-59 years, with age group midpoints (years).	
Table 4.3	Baseline US values and percentage reduction (compared to baseline 5% vaccine coverage in children) in hospitalisations and deaths due to influenza at different childhood coverage levels.	
Figure 5.6	Incidence of reported pertussis in the Netherlands, 1993 – 1997, for children aged 0-2 years, and in all age groups.	Reproduced from (de Greeff, et al., 2010).
Figure 5.7	Shift in the age distribution of rubella cases presenting at outpatient departments	

	of hospitals within the Athens region	
Table 5.1	Low and high estimates of R_0 from (Anderson & May, 1992), the critical immunisation threshold, VE estimates and the critical vaccination threshold, for selected infections.	
Figure 6.1	A monster, symbolising vaccination and its effects, being fed baskets of infants and excreting them with horns. Etching by C. Williams, 1802.	
Table 6.1	Concerns most frequently identified in 145 studies	
Table 6.2	Comparison of the serious effects of the disease and reactions to MMR	Source: MMR: The Facts (2002) Health Promotion England, reproduced in (Petts & Niemeyer, 2004).
Figure 7.1	Nomenclature of territorial units for statistics (NUTS) – 3 regions of Greece, 2016	
Figure 7.2	Difference between vaccination coverage (VC) estimates based on health insurance claims (ASHIP) and kindergarten entry examination (KEE) data, by vaccine and dose, Schleswig-Holstein, Germany	
Figure 7.4	Proportion of vaccine-related reports categorised as positive or neutral, by country.	(Larson et al., 2013).
Figure 8.5	The surveillance pyramid with examples of sources of data. † Fatal cases in surveillance.	
Figure 8.6	Laboratory reports of Haemophilus influenzae infection b by quarter and year, England, 1990-2006. The arrows indicate the introduction of universal Hib vaccination in 1992 and the Hib booster campaign in 1993	(Anonymous, 2015).
Figure 8.9	Map of India with the states of Uttar Pradesh and Bihar in blue.	
Table 8.1	Validity of case definition	
Figure 9.1	Hepatitis seroprevalence by age in Antananarivo, 2004.	
Figure 9.2	Proportion of women seronegative for rubella by age group, Cambodia, 2012.	
Figure 9.3	Percentages with protective levels of serum bactericidal antibodies, by age group, in three serological surveys.	
Figure 9.5	Log antibody concentrations and standardisation curves for anti-HAV test results in the Czech Republic (left panel) and Finland (right panel) against the reference results from Greece.	
Table 9.1	Percentage seropositive in children aged 6 – 9 months by poliovirus type and year, Kano, Nigeria.	
Figure 10.1	Individual effects and population impact of vaccination. See text for details.	
Figure 10.2	Estimated risk of cholera (per 10,000) by age in three locations in South Sudan: Tongping PoC camp (93% vaccine coverage); UN House PoC camp (95% vaccine coverage); Juba community (unvaccinated).	
Figure 10.3	Incidence of Hib meningitis in children younger than 5 years: rates per 100,000 per year and 90% confidence intervals	
Figure 10.4	Incidence of anogenital warts (Left) and chlamydia (Right) in women, by age group, 2004-12. Full lines: 15-19 years; dashed lines: 20-24 years; dotted lines: 25-29 years.	
Figure 10.5	Notified cases of diphtheria and polio in The Netherlands. The full lines represent the observed monthly counts of notified cases	
Figure 10.6	RDD design	

Figure 10.8	Distribution of outbreak sizes of 41 outbreaks with at least 2 cases.	
Figure 11.1	Causes of outbreaks of vaccine preventable diseases in the context of a vaccination programme.	
Figure 11.2	Schematic representation of causes of measles outbreaks.	
Figure 11.3	Number of reported diphtheria cases by year, (former) Soviet Union, 1965-1995.	
Figure 11.4	A. Proportion of the 2001 birth cohort who received MMR-1, by municipality, The Netherlands, January 2004. B. Number of notified rubella cases per 100.000 population, by municipality, The Netherlands, 1st September 2004-31st July 2005.	
Figure 11.5	Mumps cases by age and measles-mumps-rubella (MMR) vaccination status, Norway, September 2015–May 2016 (n=231*).	
Figure 11.6	Number of cases of a hypothetical vaccine preventable disease over time, with regular epidemic cycles pre-introduction of a vaccination programme, a 'honeymoon period' and three 'post-honeymoon' epidemics	
Figure 11.7	Epidemic curve and key time delays in vaccination in Juba, South Sudan, 2015.Bars represent numbers of suspected cases, defined as all individuals with acute watery diarrhoea regardless of dehydration.	
Figure 11.8	Cases of invasive meningococcal W disease by week of onset and pilgrim status, England and Wales, 2000 and 2001 (up to week 19).	
Figure 11.9 x2	Health promotion poster aimed at female (left) and male (right) post-secondary students, urging them to comply with mumps vaccination recommendations	
Table 11.1	Reasons for not being vaccinated, measles patients (n=272), Duisburg, Germany 2006	
Figure 12.1	The stepped wedge design with 3 areas.	
Figure 13.1	Vaccine effectiveness of acellular pertussis vaccine by confirmation method and duration of paroxysmal cough	
Table 13.1	Effectiveness of 2 doses of rotavirus vaccine against confirmed wild-type infection	
Table 13.2	Numbers infected per week in vaccinated and unvaccinated groups	
Table 14.1	Numbers of vaccinated and unvaccinated students and cases	
Table 14.2	Cases and person-time by vaccination status and prior history of zoster	
Table 14.3	Numbers of pertussis cases and contacts by vaccination status	
Table 14.4	Numbers of varicella cases, contacts and secondary attack rate by vaccination status	
Table 14.5	SUMMARY TABLE - MISSING	
Figure 15.1	Weekly VE estimate for influenza-like illness in persons aged 65 years or older	
Table 15.1	Summary Table	
Figure 16.1	BCG vaccine effectiveness (with 95% confidence bands) by time since vaccination	
Figure 16.2	Rate based and risk based vaccine effectiveness for constant rate based VE equal to 50%.	

	unexposed groups	
Table 20.3	Cases and controls with odds ratio (OR) and 95% confidence interval (CI)	
Table 20.4	Odds ratio of MS according to exposure definition and control type	
Table 20.5	Total number and relative incidence (RI) of selected adverse events after varicella vaccine	
Table 20.6	Bell's palsy episodes, relative incidence (RI) and 95% CI by risk period	
Table 20.7	Number of events relative incidence (RI) and 95% CI by dose	
Table 20.8	Summary Table	
Figure 21.1	Example of a value tree related to HPV vaccination in boys, showing the benefits for boys only.	
Table 21.1	The eight steps of the ProACT-URL framework	
Table 21.2	A benefit-risk assessment of HPV vaccination in boys.	
Table 21.3	Benefit-risk assessment of HPV vaccination in boys and young men (16-26 years).	
Table 21.4	Vaccine-specific benefits and risks of sustaining routine childhood immunisation in Africa during the COVID-19 pandemic	
Table 21.5	Effect of rotavirus vaccination programme as compared with no rotavirus vaccination programme, on deaths and hospitalizations associated with diarrhoea and intussusception in Mexico.	
Table 21.6	Benefit-risk of rotavirus vaccination in a birth cohort of 1 million Japanese children followed for 5-years post-vaccination.	
Table 21.7	Rotavirus deaths averted versus excess intussusception deaths caused under age-restricted and age-unrestricted rotavirus vaccination strategies, from Patel 2012	
Table 21.8	Estimated annual benefit-risk ratio and difference of hospitalizations due to rotavirus vaccination in France, assuming various vaccine coverages, with and without accounting for the indirect effects of vaccination	
Table 21.9	Risks and benefits of the HPV vaccine in terms of QALY change	
Table 21.10	Projected number of cases, deaths and QALYs lost due to Guillain-Barré Syndrome and meningococcal disease.	
Table 21.11	Estimated AEFI-associated years lived with disability (YLD) per 1,000,000 persons (with 95% uncertainty intervals), following vaccination with MMR, DTP and MenC (age group 13m-4yrs)	
Table 21.12	DALYs estimation following measles vaccination, and following measles infection in childhood.	

My apologies for the daunting list, most of this should be fairly easy to resolve and if you'd prefer to discuss this over a call (zoom/teams etc) I'd be happy to schedule a meeting.

Best wishes,

5.1.2e

5.1.2e

2 Park Square, Milton Park, Abingdon, OX14 4RN UK

5.1.2e @informa.com

Information Classification: General

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl *De zorg voor morgen* begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to *health and sustainability*

Information Classification: General

Information Classification: General